Ningbo Menovo Pharmaceutical Co., Ltd. (SHA:603538)

China · Delayed Price · Currency is CNY

28.59

+2.60 (10.00%)

Sep 30, 2026, 3:00 PM CST

Market Cap	9.72B +104.6%
Revenue (ttm)	1.68B +16.8%
Net Income	116.86M +20.6%
EPS	0.37 +19.5%
Shares Out	339.93M
PE Ratio	76.69
Forward PE	n/a
Dividend	0.11 (0.39%)
Ex-Dividend Date	Jul 9, 2026

Volume	47,551,922
Open	26.51
Previous Close	25.99
Day's Range	25.99 - 28.59
52-Week Range	13.55 - 50.28
Beta	-0.17
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 30, 2026

About SHA:603538

Ningbo Menovo Pharmaceutical Co., Ltd. research, develops, produces, and sells pharmaceutical products. The company’s products portfolio includes valsartan, losartan, clopidogrel, perindopril, rosuvastatin calcium, atorvastatin calcium, purin bahrain, and other products. It offers APIs, intermediates, and preparations for the treatment of cardiovascular, central nervous system, gastrointestinal tract, and other therapeutic areas. The company was founded in 2004 and is headquartered in Ningbo, China. [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2004

Employees 2,370

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 603538

Full Company Profile

Financial Performance

In 2025, SHA:603538's revenue was 1.50 billion, an increase of 9.49% compared to the previous year's 1.37 billion. Earnings were 102.23 million, an increase of 53.02%.

Financial Statements